🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jonathan Strosberg

Moffitt Cancer Center

ORCID: 0000-0001-8405-218X

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.361

Top 100%

0DataRank

Top 100%0 citations

Michelle R. Mahoney, Timothy R. Asmis, Nathan C. Hall, Sanja Karovic, Michael V. Knopp +9 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)”.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Journal of Clinical Oncology(2022)10.1200/jco.22.01013

N/A

4.9DataRank · unranked

297 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +14 more

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

The Lancet Oncology(2020)10.1016/s1470-2045(20)30323-5

N/A

0.652DataRank · unranked

76 citations

Heiko Schöder, Richard P. Baum, Ken Herrmann, Jonathan Strosberg, Martyn Caplin +3 more

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4004

N/A

0.464DataRank · unranked

21 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +15 more

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials

Cancer(2021)10.1002/cncr.33540

N/A

0.373DataRank · unranked

11 citations

Carlo Carnaghi, Roberto Buzzoni, Juan W. Valle, Fabian Herbst, Antonia Ridolfi +5 more

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad096

N/A

0.373DataRank · unranked

11 citations

Thomas A. Hope, Emily B Bergsland, Lisa Bodei, David Bushnell, Jennifer A. Chan +63 more

Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps515

N/A

0DataRank · unranked

9 citations

Katherine A. Guthrie, Syed A. Ahmad, M. Kay Washington, Brian Hemendra Ramnaraign, Nitya Raj +8 more

The role of socioeconomic deprivation in gastrointestinal cancer clinical trial enrollment at an NCI-designated comprehensive cancer center.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.785

N/A

0DataRank · unranked

0 citations

Taymeyah Al‐Toubah, Emily Coughlin, Rahul Mhaskar, Sylea Lowery, Ebin Mathew +12 more

High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3703

N/A

0DataRank · unranked

91 citations

David Taïeb, Jorge A. Carrasquillo, Daniel A. Pryma, Mayank Patel, Corina Millo +19 more

1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III CABINET Trial (Alliance A021602)

Annals of Oncology(2025)10.1016/j.annonc.2025.08.2340

N/A

0DataRank · unranked

1 citations

T. Zemla, Susan M. Geyer, Jonathan Strosberg, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos +13 more

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.361

Top 100%

0DataRank

Top 100%0 citations

Michelle R. Mahoney, Timothy R. Asmis, Nathan C. Hall, Sanja Karovic, Michael V. Knopp +9 more

Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms

Cancer(2025)10.1002/cncr.35871

N/A

0DataRank · unranked

1 citations

Leanne Brown, Varun Bansal, Baylee Bakkila, Seth J. Concors, Kiran K. Turaga +9 more

The Future of Targeted α-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field

Journal of Nuclear Medicine(2022)10.2967/jnumed.122.264805

N/A

0DataRank · unranked

10 citations

Ken Herrmann, Lisa Bodei, Jonathan Strosberg